The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Arvinas; Lantheus Medical Imaging; Novartis
Liquid biopsy AR/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.
 
Alexander Shiang
No Relationships to Disclose
 
Pradeep S. Chauhan
No Relationships to Disclose
 
Ha X. Dang
No Relationships to Disclose
 
Jace Webster
No Relationships to Disclose
 
Elisa M. Ledet
No Relationships to Disclose
 
Ramandeep K Babbra
No Relationships to Disclose
 
Wenjia Feng
No Relationships to Disclose
 
Peter K. Harris
No Relationships to Disclose
 
Ellen B. Jaeger
No Relationships to Disclose
 
Patrick Miller
No Relationships to Disclose
 
Sydney Caputo
No Relationships to Disclose
 
Giordano Fabricio Cittolin Santos
No Relationships to Disclose
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TeneoBio; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Christopher Maher
No Relationships to Disclose
 
Aadel A Chaudhuri
Leadership - Droplet Biosciences
Stock and Other Ownership Interests - Droplet Biosciences; Geneoscopy
Honoraria - Roche
Consulting or Advisory Role - Fenix Group International; Geneoscopy; Roche; Tempus
Patents, Royalties, Other Intellectual Property - US Patent No. US8685727B2
Travel, Accommodations, Expenses - Foundation Medicine; Roche
Other Relationship - Roche